Debiopharm, Genome & Company collaborate on antibody-drug conjugates

By The Science Advisory Board staff writers

February 25, 2021 -- Debiopharm and Genome & Company announced a plan to collaborate on developing antibody-drug conjugate oncology therapies.

The partnership is based on Genome & Company's oncology drug pipeline and Debiopharm's track record in oncology, with its colorectal cancer and prostate cancer drugs, oxaliplatin and triptorelin. Genome & Company will incorporate Debiopharm's Multilink antibody-drug conjugate technology, which enables high drug-to-antibody ratio, into its Gnocle drug discovery platform, which will enable clinicians to deliver cancer killing treatment to tumor cells.

Debiopharm also offers AbYlink, which attaches cancer-killing fragment crystallizable (Fc)-selective attachment of cargos, such as radioactive agents, or fluorophores to antibodies, it said.

Surface Oncology licenses anti-cancer antibody from Vaccinex
Surface Oncology will exercise an option to license an anti-C-C motif chemokine receptor 8 antibody discovered using the ActivMab antibody discovery and...
ImmunoPrecise SARS-CoV-2 antibody cocktail successful in preclinical models
ImmunoPrecise Antibodies has demonstrated that its proprietary TATX-03 PolyTope antibody cocktail against SARS-CoV-2 provides complete clearance of replication-competent...
Nucleai and Debiopharm team up for cancer drug development
Biomarker discovery company Nucleai will work with Swiss pharmaceutical developer Debiopharm to optimize development of a clinical oncology asset per...
Flywheel, AIQ to offer cancer therapy response system
Flywheel and AIQ Solutions have partnered to offer a data management and analysis system aimed at boosting scientists' understanding of treatment responses...
Overlooked benefits of using polyclonal antibodies
The benefits of polyclonal antibodies as tools for assay-specific target discovery and detection are numerous. As the future of basic research, diagnostics...

Copyright © 2021 scienceboard.net


Register below for our weekly Letter from the Editor to receive the latest Science news and insights.
Email
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter